BLK vs PFE: Which Is the Better Buy?

Side-by-side comparison of BlackRock, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-22.
BlackRock, Inc. · Financial Services
$1,042.85
+125.5% upside to fair value
Grade A High Quality
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
BLK has more upside to fair value (+125.5%). PFE trades at a lower forward P/E (9.5x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric BLK PFE
Current Price $1,042.85 $26.91
Fair Value Estimate $2,351.12 $35.00
Upside to Fair Value +125.5% +30.1%
Market Cap $162.2B $153.0B
Forward P/E 25.9x 9.5x
EV / EBITDA 16.9x 13.8x
Price / Sales 6.3x 2.4x
Price / FCF 45.2x 16.8x
Revenue Growth YoY +28.3% -1.6%
Gross Margin 59.1% 70.3%
Operating Margin 29.9% 24.7%
Return on Equity 12.0% 9.0%
Dividend Yield 0% 6.4%
FCF Yield 2.21% 5.9%
Analyst Consensus Strong Buy Hold
Investment Thesis
BLK — BlackRock, Inc.
BlackRock, Inc. is the world's largest asset manager with over $14 trillion in assets under management, operating primarily in financial services and asset management. The company benefits from a durable competitive moat driven by its scale, technology platform Aladdin, and founder-led management with CEO Laurence D. Fink at the helm since inception. BlackRock exhibits strong fundamentals includi…
PFE — Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
Metric BLK PFE
Zone Low $1,763.34 $25.00
Zone High $1,998.45 $29.00
In Buy Zone? Yes Yes
← BLK Research    PFE Research →    All Research